26/04/2024
We are delighted to announce that the Pharmaceutical Benefits Advisory Committee (PBAC) has today recommended Trikafta® for children aged 2 to 5 years who have at least one F508del mutation in the CFTR gene.
This is a positive step in the right direction and builds on the two previous decisions to recommend and list Trikafta for those 12 and above in April 2022, and more recently 6 to 11-year-olds in May 2023, both of which now have access to Trikafta through the Pharmaceutical Benefits Scheme (PBS).
There are approximately 300 young children in Australia that stand to benefit from this decision.
The recommendation now heads to the Federal Government for review and a decision as to when it will be added to the PBS.
We know that early access is vital; reducing infections, hospitalisations and increasing quality of life; and we urge all stakeholders to expedite this important listing on the PBS.
We appreciate that this recommendation was reached promptly and thank all who advocated for this important change.
Ollie is just one of the approximately 300 families with children aged 2-5 who have at least one F508del mutation and are waiting for Trikafta. You can read Ollie's story here.